The Phase I and II studies tested the safety, side-effects and immunogenicity of the potential vaccine in 100 people aged 18-60, according to the state trials register.
Typically early-stage vaccine tests on humans are based on blood readings showing an immune response in participants who have not been exposed to the virus, while the results of larger late-stage trials are based on actual infections suffered by participants in their normal lives. Russia began testing EpiVacCorona, which is being developed by Siberia’s Vector Institute, in November.was 92% effective at protecting people from COVID-19 based on interim results.
Russia has said it can inoculate 60% of its population against COVID-19 this year, and although the Sputnik V vaccine has been readily available in Moscow, the rollout across the country has been slow.EpiVacCorona will be used in mass vaccinations from March, Deputy Prime Minister Tatiana Golikova told the Interfax news agency.
Reuters
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.